Bionano Genomics (NASDAQ:BNGO) Rating Lowered to Sell at Wall Street Zen

Bionano Genomics (NASDAQ:BNGO) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Bionano Genomics Trading Down 5.3%

NASDAQ:BNGO opened at $3.04 on Friday. The stock has a fifty day moving average price of $3.30 and a two-hundred day moving average price of $3.80. The stock has a market capitalization of $10.21 million, a price-to-earnings ratio of -0.02 and a beta of 2.06. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.34 and a current ratio of 1.70. Bionano Genomics has a 1 year low of $2.68 and a 1 year high of $37.09.

Bionano Genomics (NASDAQ:BNGO) last released its quarterly earnings data on Thursday, August 14th. The company reported ($1.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.69) by $0.70. The firm had revenue of $6.73 million during the quarter, compared to analysts’ expectations of $6.90 million. Bionano Genomics had a negative return on equity of 130.31% and a negative net margin of 271.02%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Everstar Asset Management LLC purchased a new position in shares of Bionano Genomics in the first quarter valued at $126,000. Geode Capital Management LLC increased its position in shares of Bionano Genomics by 13.0% in the fourth quarter. Geode Capital Management LLC now owns 997,676 shares of the company’s stock valued at $288,000 after buying an additional 114,822 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Bionano Genomics in the fourth quarter valued at $45,000. Renaissance Technologies LLC purchased a new position in shares of Bionano Genomics in the fourth quarter valued at $46,000. Finally, Jane Street Group LLC purchased a new position in shares of Bionano Genomics in the fourth quarter valued at $118,000. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.